dr. o’malley on the safety profile of mirvetuximab in ovarian cancer
Published 4 years ago • 194 plays • Length 1:15Download video MP4
Download video MP3
Similar videos
-
0:58
dr. o’malley on the utility of mirvetuximab in ovarian cancer
-
1:13
dr. o’malley on the activity of mirvetuximab soravtansine in ovarian cancer
-
1:49
dr. moore on safety profile of mirvetuximab soravtansine in ovarian cancer
-
1:59
dr. gilbert on the safety profile of mirvetuximab soravtansine/bevacizumab in ovarian cancer
-
1:11
dr. o'malley on toxicity profiles of parp inhibitors in ovarian cancer
-
1:08
dr. o’malley on the state of immunotherapy in ovarian cancer
-
1:00
dr. o’malley on the forward ii phase ib study in ovarian cancer
-
0:51
dr. o'malley on folate-receptor alpha as a biomarker in ovarian cancer
-
50:32
precision medicine for ovarian cancer (2021)
-
32:46
ovarian cancer immunotherapy with dr. kunle odunsi
-
3:12
parp-inhibitors: a new generation of cancer drugs
-
1:09
dr. o’malley on research with immunotherapy in ovarian cancer
-
1:15
dr. o’malley on remaining questions in ovarian cancer
-
1:35
dr. o’malley on ongoing clinical trials evaluating immunotherapy in ovarian cancer
-
1:10
dr. o'malley on fda approval of maintenance rucaparib in ovarian cancer
-
1:18
dr. o'malley on the tolerability of parp inhibitors in ovarian cancer
-
1:47
dr. o’malley on antitumor activity with veliparib combo in serous ovarian cancer
-
0:58
dr. o’malley on the optimal use of parp inhibitors in advanced ovarian cancer
-
2:28
dr. moore on the role of mirvetuximab soravtansine in ovarian cancer
-
0:45
results for combination bevacizumab plus mirvetuximab soravtansine in ovarian cancer
-
1:08
dr. o'malley discusses the current role of parp inhibitors in ovarian cancer
-
2:15
dr. moore on early-phase data with mirvetuximab soravtansine in ovarian cancer